阿片类药物相关基因多态性不影响术后阿片需求:前瞻性观察研究
该单中心前瞻性研究纳入438例拟行大型骨科手术的白人成人,分析OPRM1、ABCB1、COMT四个单核苷酸多态性对术后吗啡剂量需求及不良事件的影响。404例完成最终分析,结果显示各基因多态性与吗啡剂量、代谢物浓度、不良事件或疼痛水平均无显著关联,仅ABCB1多态性与PACU内吗啡浓度相关但预测力差。
要点
- OPRM1、ABCB1、COMT多态性与术后吗啡剂量需求无显著关联。
- 基因多态性未影响吗啡相关不良事件发生率或疼痛评分。
- ABCB1多态性与PACU吗啡浓度相关但模型预测力差(R=0.04)。
核心结论
- OPRM1、ABCB1、COMT的单核苷酸多态性与术后吗啡需求、疼痛水平或不良反应之间未显示主要关联。
研究设计与样本
- 单中心前瞻性观察研究,法国巴黎大学医院2007年1月2日至2011年11月15日进行。
- 共438例拟行大型骨科手术(脊柱、髋、膝)全身麻醉的白人成人,404例完成最终分析。
主要发现
- 达到疼痛缓解的平均±SD吗啡剂量在PACU为15.8±8.8 mg,在患者自控静脉给药24 h期间为22.7±18.6 mg。
- 37%的患者观察到吗啡相关不良事件。
- 任何基因多态性与吗啡剂量、吗啡3-葡萄糖醛酸苷及吗啡6-葡萄糖醛酸苷浓度、吗啡相关不良事件或疼痛水平均无关系。
- 仅在PACU中,P-糖蛋白(ABCB1)外显子21和外显子26多态性与吗啡浓度显著相关,但模型预测力差(R=0.04)。
临床怎么用
- 基于OPRM1、ABCB1、COMT基因型常规预测术后吗啡需求或不良反应的价值有限。
局限性
- 单中心研究,仅纳入白人成人,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among the various factors that may influence the pharmacological response to opioids, genetic polymorphisms [single nucleotide polymorphisms (SNP)] have generated some interest. OBJECTIVES: To examine the influence on morphine dose requirements and adverse events in the postoperative period of four SNP [opioid receptor mu1 (OPRM1), ATP-binding cassette subfamily B, member 1 (ABCB1) ex-21 and ex-26, catechol-o-methyltransferase (COMT)] in candidate genes involved in morphine pharmacodynamics and pharmacokinetics. DESIGN: A single centre prospective study. SETTING: University Hospital, Paris, France, from 2 January 2007 to 15 November 2011. PATIENTS: A total of 438 white adults scheduled for major orthopaedic surgery (spine, hip and knee) under general anaesthesia. The main exclusion criteria were receiving opioids for chronic pain, nonopioid drugs within 2 days prior to surgery, pregnancy, renal insufficiency, sleep apnoea obstruction syndrome, morbid obesity, severe hepatic impairment, cognitive dysfunction. INTERVENTIONS: Assays of plasma concentrations of morphine and metabolites (morphine 3-glucuronide and morphine 6-glucuronide) were performed and common polymorphisms in four candidate genes [OPRM1 A118G rs1799971; P-glycoprotein (ABCB1) T3435C (rs1045642) and G2677T/A (rs2032582); COMT Val 158 Met (rs4680)] were analysed.Morphine was titrated by staff in the postanaesthesia care unit (PACU) and in the ward patient-controlled intravenous analgesia was used for 24 h. MAIN OUTCOME MEASURES: The dose of morphine required to achieve pain relief and the influence of SNP in genes involved in morphine pharmacodynamics and kinetics on morphine dose requirements. Secondary endpoints were the concentrations of morphine, morphine 6-glucuronide and morphine 3-gluguronide, the proportion of patients requiring a rescue analgesic and the proportion of morphine-related adverse events. RESULTS: A total of 404 patients completed the study to final analysis. The mean ± SD morphine dose to achieve pain relief was 15.8 ± 8.8 mg in the PACU and 22.7 ± 18.6 mg during patient-controlled intravenous administration. Morphine-related adverse events were observed in 37%. There was no relationship between any genetic polymorphisms and morphine dose, morphine 3-gluguronide and morphine 6-glucuronide concentration, morphine-related adverse events or pain level. In the PACU only, P-glycoprotein polymorphisms (ex-21; ex-26) were significantly associated with morphine concentration but the prediction of the model was poor (R = 0.04) CONCLUSION: No major relationship has been demonstrated between SNP of OPRM1, ABCB1, COMT and morphine requirement, pain level or adverse effects in the postoperative period. TRIAL REGISTRATION: NCT00822549 (www.clinicaltrials.gov).
引用
- Aubrun F, Zahr N, Langeron O, et al. Opioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study. Eur J Anaesthesiol. 2018. PMID: 29474345. doi:10.1097/EJA.0000000000000793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。